| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.99 [0.83, 1.18] | | < 1 | | 0% | 1 study (1/-) | 54.6 % | NA | not evaluable | | crucial | - |
| progression or deaths (PFS) | 0.77 [0.54, 1.09] | | < 1 | | 0% | 1 study (1/-) | 93.0 % | NA | not evaluable | | important | - |
| DOR | 0.35 [0.20, 0.62] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 0.36 [0.26, 0.49] | | > 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (grade 3-4) | 0.37 [0.27, 0.52] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.66 [0.43, 1.03] | | < 1 | | 0% | 1 study (1/-) | 96.7 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 1.01 [0.74, 1.39] | | < 1 | | 0% | 1 study (1/-) | 46.3 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 0.50 [0.31, 0.81] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.13 [0.09, 0.21] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 0.10 [0.07, 0.15] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 1.82 [0.16, 20.16] | | < 1 | | 0% | 1 study (1/-) | 31.4 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 0.46 [0.26, 0.79] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 3.64 [0.16, 81.12] | | < 1 | | 0% | 1 study (1/-) | 21.0 % | NA | not evaluable | | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 0.45 [0.02, 13.55] | | < 1 | | 0% | 1 study (1/-) | 67.4 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 1.82 [0.06, 54.35] | | < 1 | | 0% | 1 study (1/-) | 36.7 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.05 [0.02, 0.13] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Arthritis TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.25 [0.05, 1.24] | | < 1 | | 0% | 1 study (1/-) | 95.5 % | NA | not evaluable | | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.45 [0.02, 13.55] | | < 1 | | 0% | 1 study (1/-) | 67.4 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.68 [0.15, 3.05] | | < 1 | | 0% | 1 study (1/-) | 69.3 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.36 [0.07, 1.86] | | < 1 | | 0% | 1 study (1/-) | 88.8 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 3.64 [0.16, 81.12] | | < 1 | | 0% | 1 study (1/-) | 21.0 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.11 [0.01, 0.89] | | < 1 | | 0% | 1 study (1/-) | 98.0 % | NA | not evaluable | | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.15 [0.01, 3.01] | | < 1 | | 0% | 1 study (1/-) | 89.0 % | NA | not evaluable | | non important | - |
| Gastritis TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 1.82 [0.06, 54.35] | | < 1 | | 0% | 1 study (1/-) | 36.7 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 5.48 [0.27, 109.88] | | < 1 | | 0% | 1 study (1/-) | 13.6 % | NA | not evaluable | | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 0.45 [0.02, 13.55] | | < 1 | | 0% | 1 study (1/-) | 67.4 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 0.91 [0.13, 6.48] | | < 1 | | 0% | 1 study (1/-) | 53.9 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.74 [0.28, 26.45] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 6.46 [0.79, 52.82] | | < 1 | | 0% | 1 study (1/-) | 4.2 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.04 [0.00, 0.62] | | < 1 | | 0% | 1 study (1/-) | 98.8 % | NA | not evaluable | | non important | - |
| Myocarditis TRAE (grade 3-4) | 3.64 [0.16, 81.12] | | < 1 | | 0% | 1 study (1/-) | 21.0 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 1.82 [0.06, 54.35] | | < 1 | | 0% | 1 study (1/-) | 36.7 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.06 [0.00, 0.97] | | < 1 | | 0% | 1 study (1/-) | 97.5 % | NA | not evaluable | | non important | - |
| Nephritis TRAE (grade 3-4) | 3.64 [0.16, 81.12] | | < 1 | | 0% | 1 study (1/-) | 21.0 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.01 [0.00, 0.09] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.11 [0.01, 2.13] | | < 1 | | 0% | 1 study (1/-) | 92.5 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 3.64 [0.16, 81.12] | | < 1 | | 0% | 1 study (1/-) | 21.0 % | NA | not evaluable | | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 1.82 [0.06, 54.35] | | < 1 | | 0% | 1 study (1/-) | 36.7 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.23 [0.01, 5.02] | | < 1 | | 0% | 1 study (1/-) | 82.3 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 3.64 [0.16, 81.12] | | < 1 | | 0% | 1 study (1/-) | 21.0 % | NA | not evaluable | | non important | - |
| Sepsis TRAE (grade 3-4) | 0.91 [0.06, 14.56] | | < 1 | | 0% | 1 study (1/-) | 52.7 % | NA | not evaluable | | non important | - |
| Stevens-Johnson syndrome TRAE (grade 3-4) | 1.82 [0.06, 54.35] | | < 1 | | 0% | 1 study (1/-) | 36.7 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.02 [0.00, 0.29] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.09 [0.00, 1.64] | | < 1 | | 0% | 1 study (1/-) | 94.6 % | NA | not evaluable | | non important | - |
